Sandoz approval for generic Ozempic in Canada draws mixed outlook
TradingView News market talk says Sandoz’s Canada approval for a generic version of Novo Nordisk’s Ozempic is positive, but RBC Capital Markets says the size of the upside is difficult to gauge.
Sandoz Group's approval for a generic version of Novo Nordisk's Ozempic in Canada is positive, but RBC Capital Markets' Harry Sephton said it is difficult to gauge how much of a lift it will provide for the Swiss generic-drug manufacturer. Sephton said the overall generic opportunity remains uncertain given the limited information available.